ConductScience.org, home

Comparison · NCT02771977-2d59422d

Drug-specific Alert vs Usual Care: Percentage of Subjects With Chart Documentation of AKI

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Drug-specific Alert vs Usual Care: Percentage of Subjects With Chart Documentation of AKI. Trial comparisons, record NCT02771977-2d59422d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02771977-2d59422d

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.3950.3760.414wilson
Risk in group 20.3780.3590.397wilson
Risk difference, group 1 minus group 20.0168-0.010.0436newcombe hybrid score
Risk ratio, group 1 over group 21.040.9741.12log
Odds ratio, group 1 over group 21.070.9581.2log
Number needed to treat, for one more participant with the outcome on Drug-specific Alert than on Usual Care59.6from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: usual care.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Drug-specific Alert
A drug-specific AKI alert, including information about the drug of interest as well as the presence of AKI will be fired.~Drug-specific alert: A drug-specific alert, informing the provider of the presence of AKI as well as recent exposure to a potentially nephrotoxic agent, will be fired.
1,0002,532OG001
Group 2Usual CareNo alert will be fired.9562,528OG000

Outcome

Type
SECONDARY
Title
Percentage of Subjects With Chart Documentation of AKI
Description
Percentage of subjects with chart documentation of AKI by post-discharge ICD-10 codes and by chart adjudication
Time frame
Assessed from time of randomization through to date of index hospitalization discharge, up to 365 days post randomization
Population

Source ClinicalTrials.gov

Trial

Title
Drug-Targeted Alerts for Acute Kidney Injury
NCT number
NCT02771977
Phases
NA
Conditions
Acute Kidney Injury
Interventions
Drug-specific alert
Lead sponsor
Yale University
Results first posted
2023-06-29

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02771977-2d59422d